Elvia Cowan, SVP, Finance and Chief Accounting Officer of Vaxcyte, Inc. (NASDAQ:PCVX), filed a Form 4 on November 4, 2026, disclosing transactions dated November 2, 2026, involving the exercise of stock options and the subsequent sale of common stock under a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise: Cowan exercised a fully vested stock option covering 3,000 shares of common stock at an exercise price of $25.92 per share on November 2, 2026.
  • First sale tranche: 2,414 shares were sold at a weighted-average price of $60.765, with individual prices ranging from $60.345 to $61.325.
  • Second sale tranche: 586 shares were sold at a weighted-average price of $61.547, with individual prices ranging from $61.425 to $61.92.
  • Remaining ownership: Following all reported transactions, Cowan directly beneficially owned 27,860 shares of common stock.
  • Remaining options: Cowan holds 71,068 stock options (right to buy) with an exercise price of $25.92 and an expiration date of August 8, 2032.
  • 10b5-1 plan: The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025, according to the filing.

Cowan's November 2026 Option Exercise and Share Sales at Vaxcyte

According to the Form 4 filed with the SEC, Elvia Cowan, serving as SVP, Finance and Chief Accounting Officer at Vaxcyte, Inc. (NASDAQ:PCVX), reported three transactions in the company's common stock on November 2, 2026. The filing indicates that the transactions were made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

The filing discloses that Cowan first exercised a stock option to acquire 3,000 shares at an exercise price of $25.92 per share. The underlying stock option was described in the filing as fully vested and exercisable, with an expiration date of August 8, 2032. Following that exercise, Cowan's directly held common stock position stood at 30,860 shares, according to the filing.

Cowan then disposed of the 3,000 shares across two sale transactions on the same date. The filing states that 2,414 shares were sold at a weighted-average price of $60.765, with actual prices ranging from $60.345 to $61.325, and that 586 shares were sold at a weighted-average price of $61.547, with actual prices ranging from $61.425 to $61.92. Both sales were conducted under a Rule 10b5-1 trading plan adopted on December 8, 2025, as noted in the filing's explanation of responses. After both sales, the filing reports Cowan's direct beneficial ownership of common stock at 27,860 shares, with 71,068 stock options remaining.

What Was Disclosed

Vaxcyte SVP and CAO Elvia Cowan filed a Form 4 reporting a November 2, 2026, option exercise of 3,000 shares at $25.92 and the subsequent sale of those shares in two tranches under a pre-established Rule 10b5-1 plan, leaving her with 27,860 shares directly owned.